Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway

Cancer Cell

Volumn 5, Issue 5, 2004, Pages 501-512

  Wang, Yan ^a   Engels, Ingo H ^a   Knee, Deborah A ^a   Nasoff, Marc ^a   Deveraux, Quinn L ^a   Quon, Kim C ^a  

^a Genomics Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DEATH RECEPTOR 5; DEATH RECEPTOR 5 AGONIST; ONCOPROTEIN; PROCASPASE 8; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CATALYSIS; CELL SURFACE; CONTROLLED STUDY; DRUG POTENCY; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MALE; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN PROCESSING; STIMULATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALIA;

EID: 2342495721     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00113-8     Document Type: Article

References (54)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer. 2:2002;420-430
2. Berns K., Hijmans E.M., Bernards R. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene. 15:1997;1347-1356
3. Boatright K.M., Renatus M., Scott F.L., Sperandio S., Shin H., Pedersen I.M., Ricci J.E., Edris W.A., Sutherlin D.P., Green D.R., Salvesen G.S. A unified model for apical caspase activation. Mol. Cell. 11:2003;529-541
4. Bouchard C., Thieke K., Maier A., Saffrich R., Hanley-Hyde J., Ansorge W., Reed S., Sicinski P., Bartek J., Eilers M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18:1999;5321-5333
5. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:1999;263-269
6. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:2002;493-502
7. D'Cruz C.M., Gunther E.J., Boxer R.B., Hartman J.L., Sintasath L., Moody S.E., Cox J.D., Ha S.I., Belka G.K., Golant A., et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7:2001;235-239
8. Deveraux Q.L., Welsh K., Reed J.C. Purification and use of recombinant inhibitor of apoptosis proteins as caspase inhibitors. Methods Enzymol. 322:2000;154-161
9. Dolma S., Lessnick S.L., Hahn W.C., Stockwell B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 3:2003;285-296
10. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 1:2002;31-36
11. Eilers M., Picard D., Yamamoto K.R., Bishop J.M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature. 340:1989;66-68
12. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15:2001;50-65
13. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128
14. Fantin V.R., Berardi M.J., Scorrano L., Korsmeyer S.J., Leder P. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell. 2:2002;29-42
15. Felsher D.W. Cancer revoked. oncogenes as therapeutic targets Nat. Rev. Cancer. 3:2003;375-380
16. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 17:2003;1115-1129
17. Fulda S., Meyer E., Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 21:2002;2283-2294
18. Grandori C., Cowley S.M., James L.P., Eisenman R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16:2000;653-699
19. Green D.R., Evan G.I. A matter of life and death. Cancer Cell. 1:2002;19-30
20. Griffith T.S., Rauch C.T., Smolak P.J., Waugh J.Y., Boiani N., Lynch D.H., Smith C.A., Goodwin R.G., Kubin M.Z. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162:1999;2597-2605
21. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468
22. Hahn W.C., Dessain S.K., Brooks M.W., King J.E., Elenbaas B., Sabatini D.M., DeCaprio J.A., Weinberg R.A. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22:2002;2111-2123
23. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
24. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science. 278:1997;1064-1068
25. Hueber A.O., Zornig M., Lyon D., Suda T., Nagata S., Evan G.I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309
26. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P., Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7:2001;954-960
27. Juin P., Hueber A.O., Littlewood T., Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13:1999;1367-1381
28. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 101:2003;2797-2803
29. Klefstrom J., Arighi E., Littlewood T., Jaattela M., Saksela E., Evan G.I., Alitalo K. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO J. 16:1997;7382-7392
30. Klefstrom J., Verschuren E.W., Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J. Biol. Chem. 277:2002;43224-43232
31. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., Fong S., Schwall R., Sinicropi D., Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8:2002;274-281
32. Leverkus M., Sprick M.R., Wachter T., Denk A., Brocker E.B., Walczak H., Neumann M. TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes. differential contribution of TRAIL receptors 1 and 2 J. Invest. Dermatol. 121:2003;149-155
33. Lindstrom M.S., Wiman K.G. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin. Cancer Biol. 12:2002;381-387
34. Mouzakiti A., Packham G. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br. J. Haematol. 122:2003;61-69
35. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene. 18:1999;3004-3016
36. Oster S.K., Ho C.S., Soucie E.L., Penn L.Z. The myc oncogene. MarvelouslY Complex Adv. Cancer Res. 84:2002;81-154
37. Ozoren N., El-Deiry W.S. Cell surface Death Receptor signaling in normal and cancer cells. Semin. Cancer Biol. 13:2003;135-147
38. Pelengaris S., Khan M., Evan G. c-myc. more than just a matter of life and death Nat. Rev. Cancer. 2:2002;764-776
39. Peter M.E. The TRAIL DISCussion. it is FADD and caspase-8! Cell Death Differ. 7:2000;759-760
40. Phillips A.C., Ernst M.K., Bates S., Rice N.R., Vousden K.H. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol. Cell. 4:1999;771-781
41. Reddy A., Kaelin W.G. Jr. Using cancer genetics to guide the selection of anticancer drug targets. Curr. Opin. Pharmacol. 2:2002;366-373
42. Sager J.A., Lengauer C. New paradigms for cancer drug discovery. Cancer Biol. Ther. 2:2003;452-455
43. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687
44. Shivapurkar N., Reddy J., Matta H., Sathyanarayana U.G., Huang C.X., Toyooka S., Minna J.D., Chaudhary P.M., Gazdar A.F. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene. 21:2002;8510-8514
45. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity. 18:2003;1-6
46. Sprick M.R., Rieser E., Stahl H., Grosse-Wilde A., Weigand M.A., Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21:2002;4520-4530
47. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., Behm F.G., Look A.T., Lahti J.M., Kidd V.J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6:2000;529-535
48. Torrance C.J., Agrawal V., Vogelstein B., Kinzler K.W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19:2001;940-945
49. Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., Wahl G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function. a mechanism for oncogene-induced genetic instability Mol. Cell. 9:2002;1031-1044
50. van Noesel M.M., Pieters R., Voute P.A., Versteeg R. The N-myc paradox. N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis Cancer Lett. 197:2003;165-172
51. Wang S., El-Deiry W.S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. USA. 100:2003;15095-15100
52. Wu G.S., Burns T.F., McDonald E.R. 3rd, Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:1997;141-143
53. Yoshida T., Maeda A., Tani N., Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 507:2001;381-385
54. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 290:2000;989-992